Tags

Type your tag names separated by a space and hit enter

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis.
Int J Infect Dis. 2020 May; 94:91-95.IJ

Abstract

BACKGROUND

An outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan, China; the epidemic is more widespread than initially estimated, with cases now confirmed in multiple countries.

AIMS

The aim of this meta-analysis was to assess the prevalence of comorbidities in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients and the risk of underlying diseases in severe patients compared to non-severe patients.

METHODS

A literature search was conducted using the databases PubMed, EMBASE, and Web of Science through February 25, 2020. Odds ratios (ORs) and 95% confidence intervals (CIs) were pooled using random-effects models.

RESULTS

Seven studies were included in the meta-analysis, including 1 576 infected patients. The results showed the most prevalent clinical symptom was fever (91.3%, 95% CI: 86-97%), followed by cough (67.7%, 95% CI: 59-76%), fatigue (51.0%, 95% CI: 34-68%) and dyspnea (30.4%, 95% CI: 21-40%). The most prevalent comorbidities were hypertension (21.1%, 95% CI: 13.0-27.2%) and diabetes (9.7%, 95% CI: 7.2-12.2%), followed by cardiovascular disease (8.4%, 95% CI: 3.8-13.8%) and respiratory system disease (1.5%, 95% CI: 0.9-2.1%). When compared between severe and non-severe patients, the pooled OR of hypertension, respiratory system disease, and cardiovascular disease were 2.36 (95% CI: 1.46-3.83), 2.46 (95% CI: 1.76-3.44) and 3.42 (95% CI: 1.88-6.22) respectively.

CONCLUSION

We assessed the prevalence of comorbidities in the COVID-19 patients and found that underlying disease, including hypertension, respiratory system disease and cardiovascular disease, may be risk factors for severe patients compared with non-severe patients.

Authors+Show Affiliations

Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China; The First Clinical Medical School of Lanzhou University, Lanzhou, China.Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China; Key Laboratory for Gastrointestinal Diseases of Gansu Province, The First Hospital of Lanzhou University, Lanzhou, China.Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China; Gastrointestinal Endoscopy Center, Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China.Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China; The First Clinical Medical School of Lanzhou University, Lanzhou, China.Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China; Gastrointestinal Endoscopy Center, Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China.Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China; Key Laboratory for Gastrointestinal Diseases of Gansu Province, The First Hospital of Lanzhou University, Lanzhou, China; Gastrointestinal Endoscopy Center, Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China.Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China; Key Laboratory for Gastrointestinal Diseases of Gansu Province, The First Hospital of Lanzhou University, Lanzhou, China; Gastrointestinal Endoscopy Center, Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China.The First Clinical Medical School of Lanzhou University, Lanzhou, China.Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China; Key Laboratory for Gastrointestinal Diseases of Gansu Province, The First Hospital of Lanzhou University, Lanzhou, China. Electronic address: wangyuping@lzu.edu.cn.Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China; Key Laboratory for Gastrointestinal Diseases of Gansu Province, The First Hospital of Lanzhou University, Lanzhou, China; Gastrointestinal Endoscopy Center, Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China. Electronic address: zhouyn@lzu.edu.cn.

Pub Type(s)

Journal Article
Meta-Analysis
Systematic Review

Language

eng

PubMed ID

32173574

Citation

Yang, Jing, et al. "Prevalence of Comorbidities and Its Effects in Patients Infected With SARS-CoV-2: a Systematic Review and Meta-analysis." International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, vol. 94, 2020, pp. 91-95.
Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-95.
Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., Ji, R., Wang, H., Wang, Y., & Zhou, Y. (2020). Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, 94, 91-95. https://doi.org/10.1016/j.ijid.2020.03.017
Yang J, et al. Prevalence of Comorbidities and Its Effects in Patients Infected With SARS-CoV-2: a Systematic Review and Meta-analysis. Int J Infect Dis. 2020;94:91-95. PubMed PMID: 32173574.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. AU - Yang,Jing, AU - Zheng,Ya, AU - Gou,Xi, AU - Pu,Ke, AU - Chen,Zhaofeng, AU - Guo,Qinghong, AU - Ji,Rui, AU - Wang,Haojia, AU - Wang,Yuping, AU - Zhou,Yongning, Y1 - 2020/03/12/ PY - 2020/02/28/received PY - 2020/03/04/revised PY - 2020/03/05/accepted PY - 2020/3/17/pubmed PY - 2020/5/22/medline PY - 2020/3/17/entrez KW - COVID-19 KW - Clinical characteristics KW - Comorbidities KW - Epidemiology KW - Meta-analysis KW - SARS-CoV-2 SP - 91 EP - 95 JF - International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases JO - Int J Infect Dis VL - 94 N2 - BACKGROUND: An outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan, China; the epidemic is more widespread than initially estimated, with cases now confirmed in multiple countries. AIMS: The aim of this meta-analysis was to assess the prevalence of comorbidities in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients and the risk of underlying diseases in severe patients compared to non-severe patients. METHODS: A literature search was conducted using the databases PubMed, EMBASE, and Web of Science through February 25, 2020. Odds ratios (ORs) and 95% confidence intervals (CIs) were pooled using random-effects models. RESULTS: Seven studies were included in the meta-analysis, including 1 576 infected patients. The results showed the most prevalent clinical symptom was fever (91.3%, 95% CI: 86-97%), followed by cough (67.7%, 95% CI: 59-76%), fatigue (51.0%, 95% CI: 34-68%) and dyspnea (30.4%, 95% CI: 21-40%). The most prevalent comorbidities were hypertension (21.1%, 95% CI: 13.0-27.2%) and diabetes (9.7%, 95% CI: 7.2-12.2%), followed by cardiovascular disease (8.4%, 95% CI: 3.8-13.8%) and respiratory system disease (1.5%, 95% CI: 0.9-2.1%). When compared between severe and non-severe patients, the pooled OR of hypertension, respiratory system disease, and cardiovascular disease were 2.36 (95% CI: 1.46-3.83), 2.46 (95% CI: 1.76-3.44) and 3.42 (95% CI: 1.88-6.22) respectively. CONCLUSION: We assessed the prevalence of comorbidities in the COVID-19 patients and found that underlying disease, including hypertension, respiratory system disease and cardiovascular disease, may be risk factors for severe patients compared with non-severe patients. SN - 1878-3511 UR - https://www.unboundmedicine.com/medline/citation/32173574/Prevalence_of_comorbidities_and_its_effects_in_patients_infected_with_SARS_CoV_2:_a_systematic_review_and_meta_analysis_ DB - PRIME DP - Unbound Medicine ER -